NCT01418651

Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population

Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population: an Open-label Study

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Banner Health · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

Participants will undertake a 12-week, open-label study of milnacipran in a well-characterized cohort of patients with fibromyalgia syndrome (FMS) who are 65 years and older to investigate the short-term efficacy and safety of this drug in the elderly population. The investigators hypothesize that milnacipran will be effective in treating fibromyalgia syndrome (FMS), and will be prove to be safe when patients are selected for the absence of pre-existing blood pressure abnormalities and other serious medical conditions.

Conditions

• Fibromyalgia

Interventions

Type	Name	Description
DRUG	Savella	milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)

Timeline

• Start date: 2011-03-01
• Primary completion: 2011-08-01
• Completion: 2011-08-01
• First posted: 2011-08-17
• Last updated: 2011-08-17

Locations

1 site across 1 country: United States